Biofluid-based biomarker panels toward personalized medicine in dementia diagnostics

Henrik Zetterberg

doi:10.1002/alz.70178

Biofluid-based biomarker panels toward personalized medicine in dementia diagnostics

Alzheimers Dement. 2025 Jun;21(6):e70178. doi: 10.1002/alz.70178.

Author

Henrik Zetterberg^{1

2

3

4

5

6}

Affiliations

¹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
² Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
³ Department of Neurodegenerative Disease, University College London Institute of Neurology, London, UK.
⁴ UK Dementia Research Institute at University College London, London, UK.
⁵ Hong Kong Center for Neurodegenerative Diseases, InnoHK, Hong Kong, China.
⁶ Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Abstract

Alzheimer's & Dementia publishes a set of papers exploring the diagnostic and prognostic capabilities of a novel cutting-edge multiplexed biomarker measurement technology across neurodegenerative dementias.

Publication types

Editorial

MeSH terms

Alzheimer Disease* / diagnosis
Biomarkers* / cerebrospinal fluid
Dementia* / diagnosis
Humans
Precision Medicine* / methods

Substances

Biomarkers

Abstract

Publication types

MeSH terms

Substances

Grants and funding